REFERENCES
1. Bansal R, Rakshit S, Kumar S. Extramedullary disease in multiple myeloma. Blood Cancer J 2021;11:161.
2. He J, Yue X, He D, et al. Multiple extramedullary-bone related and/or extramedullary extraosseous are independent poor prognostic factors in patients with newly diagnosed multiple myeloma. Front Oncol 2021;11:668099.
3. Beksac M, Seval GC, Kanellias N, et al. A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma study group and barcelona university: analysis of parameters that improve outcome. Haematologica 2020;105:201-8.
4. Ribatti D, Vacca A. New insights in anti-angiogenesis in multiple myeloma. Int J Mol Sci 2018;19:2031.
5. Ribatti D, Nico B, Vacca A. Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma. Oncogene 2006;25:4257-66.
6. Bastos ACSF, Blunck CB, Emerenciano M, Gimba ERP. Osteopontin and their roles in hematological malignancies: splice variants on the new avenues. Cancer Lett 2017;408:138-43.
7. Duletić-Načinović A, Gačić V, Valković T, et al. Concurrent elevations of VEGF, osteopontin and MCP-1 serum levels are independent predictors of survival in patients with diffuse large B-cell lymphoma. Acta Haematol 2016;136:52-61.
8. Valković T, Babarović E, Lučin K, et al. Plasma levels of osteopontin and vascular endothelial growth factor in association with clinical features and parameters of tumor burden in patients with multiple myeloma. Biomed Res Int 2014;2014:513170.
9. Saeki Y, Mima T, Ishii T, et al. Enhanced production of osteopontin in multiple myeloma: clinical and pathogenic implications. Br J Haematol 2003;123:263-70.
10. Gagelmann N, Eikema DJ, Iacobelli S, et al. Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the chronic malignancies working party of the EBMT. Haematologica 2018;103:890-7.
11. Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol 2010;21:325-30.
12. Pour L, Sevcikova S, Greslikova H, et al. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica 2014;99:360-4.
13. Pasmantier MW, Azar HA. Extraskeletal spread in multiple plasma cell myeloma: a review of 57 autopsied cases. Cancer 1969;23:167-74.
14. Deng S, Xu Y, An G, et al. Features of extramedullary disease of multiple myeloma: high frequency of p53 deletion and poor survival: a retrospective single-center study of 834 cases. Clin Lymphoma Myeloma Leuk 2015;15:286-91.
15. Mulligan G, Lichter DI, Di Bacco A, et al. Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood 2014;123:632-9.
16. Varga C, Xie W, Laubach J, et al. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. Br J Haematol 2015;169:843-50.
17. Roccaro AM, Mishima Y, Sacco A, et al. CXCR4 Regulates extra-medullary myeloma through epithelial-mesenchymal-transition-like transcriptional activation. Cell Rep 2015;12:622-35.
18. Azab AK, Quang P, Azab F, et al. P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. Blood 2012;119:1468-78.
19. Dahl IM, Rasmussen T, Kauric G, Husebekk A. Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma. Br J Haematol 2002;116:273-7.
20. Hedvat CV, Comenzo RL, Teruya-Feldstein J, et al. Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma. Br J Haematol 2003;122:728-44.
21. Montefusco V, Gay F, Spada S, et al. Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs. Haematologica 2020;105:193-200.
22. Mangiacavalli S, Pompa A, Ferretti V, et al. The possible role of burden of therapy on the risk of myeloma extramedullary spread. Ann Hematol 2017;96:73-80.
23. Sfiridaki A, Miyakis S, Pappa C, et al. Circulating osteopontin: a dual marker of bone destruction and angiogenesis in patients with multiple myeloma. J Hematol Oncol 2011;4:22.
24. Cerny J, Fadare O, Hutchinson L, Wang SA. Clinicopathological features of extramedullary recurrence/relapse of multiple myeloma. Eur J Haematol 2008;81:65-9.
